| Georges El Nahas, Ph.D. Assistant Professor Department of Psychiatry and Behavioral Sciences 68 President Street, BEB 103-P Charleston, SC 29425 843-876-2447 843-876-2344 Fax elnahas@musc.edu |
Michael E. Saladin, Ph.D. Professor Department of Health Sciences and Research College of Health Professions 77 President Street Charleston, SC 29425 843-792-5306 843-792-1358 Fax saladinm@musc.edu |
Graham Warren, M.D., Ph.D. Professor Vice Chairman for Research in Radiation Oncology Department of Radiation Oncology 169 Ashley Avenue Charleston, SC 29425 843-876-2295 843-792-5498 Fax warrengw@musc.edu |
| Dianne Wilson Program Coordinator Department of Psychiatry & Behavioral Sciences 68 President Street Charleston, SC 29425 843-876-2437 843-876-2344 Fax wilsoncd@musc.edu |
Nathaniel L. Baker, MS Assistant Professor Department of Public Health Sciences Phone: 843-792-5028 bakern@musc.edu |
Matthew J. Carpenter, Ph.D., is the Flora McLeod Edwards Distinguished Chair in Cancer Research and a clinical psychologist with strong research expertise in behavioral science, particularly addictive behaviors and smoking cessation. In his associate director role, he provides strategic direction, research leadership, and program development to advance behavioral, epidemiologic, and population science across the cancer continuum, with an emphasis on cancer prevention, early detection, health disparities, survivorship, and implementation science.
Dr. Cumming's training and research interests are in the study of health related behaviors, especially tobacco use prevention and cessation. His research is primarily population based with a focus on smoking cessation, consumer risk perceptions, the impact of cigarette design on smoking behaviors, and the evaluation of public policies on tobacco use behaviors. Recognized internationally for his work in tobacco epidemiology and smoking cessation, Dr. Cummings has guided global public policy and regulations in the marketing and distribution of nicotine products. This work has involved designing studies to understand factors involved in predicting uptake and cessation of tobacco use and the testing of interventions to alter tobacco use behaviors at both the individual and population level. In 2002, Dr. Cummings established the International Tobacco Research Policy Evaluation Project (ITC Project) to evaluate the behavioral impacts of national level tobacco control policies implemented as part of the WHO Framework Convention on Tobacco Control (FCTC). This international project began in 2002 and involves over 100 scientific colleagues from more than 20 countries and includes a wide range of research projects ranging from those focused on biological factors that influence tobacco use to the impact of health warnings and public education campaigns on representative populations of smokers. As part of his work with the ITC Project he has served as the PI on three large multi-institutional NIH grants (P50 CA111236: 2004-2009, P01 CA138389: 2009-2016, P01 CA200512: 2016-2021). Data from the ITC Project has become an important source of the evidence base used by governments and public health advocates to support tobacco control policy initiatives around the world. Over his 35-year career he has directed more than 70 grants and contracts and has published over 430 scientific papers including landmark reports for the Office of the Surgeon General, the National Cancer Institute, the International Agency for Research on Cancer, and the Institute of Medicine.
The Innovation Sciences Unit is led by Dr. Jennifer Dahne, an Associate Professor within the Addiction Sciences Division of the Department of Psychiatry & Behavioral Sciences. Dr. Dahne is an academic entrepreneur who has received five small business grants from various NIH institutes (NIMH, NIDA, NCATS, NIMHD) totaling more than $3M. Dr. Dahne has co-founded two faculty-led spinout companies, both of which are in the digital health space. Dr. Dahne has led the development, evaluation, and commercialization of five commercially available digital health products to date. These products have been evaluated via rigorous randomized clinical trials which have accrued more than 1,000 patients. In addition to entrepreneurial ventures, Dr. Dahne directs a research laboratory within the Addiction Sciences Division that has received numerous traditional NIH grant awards including R01, R21, and K23 funding. Dr. Dahne is passionate about translating academic innovations into products that can be widely disseminated and commercialized in order to improve public health.
Program Director
Dr. Erin A. McClure is a behavioral psychologist and an Associate Professor in the Department of Psychiatry and Behavioral Sciences at the Medical University of South Carolina. Dr. McClure earned her B.S. in Psychology and Neuroscience from Allegheny College and her Ph.D. in Psychology from the University of Florida. The overarching goal of Dr. McClure’s program of research is broadly focused on reducing the harmful impact of cannabis and tobacco/nicotine product use across the lifespan. Her research has focused on refining and evaluating strategies to improve long-term abstinence and prevent relapse, as well as pursuing harm reduction strategies to minimize the adverse impact of substance use; all utilizing technology to improve remote procedures and data quality, as well as to increase reach and accessibility.
Research Interests: Dr. Rojewski is a psychologist with a focus on cancer control. Her research interests include tobacco treatment interventions for populations with medical comorbidities and implementing tobacco treatment interventions in the health care system.
Benjamin Toll, Ph.D., a professor of public health sciences and psychiatry at MUSC, specializes in the treatment of tobacco use disorders and improvement of health behaviors. As associate director, his goal is to provide well-structured and effective education and training opportunities for pre- and post-doctoral students and junior faculty at Hollings Cancer Center.
Executive Council
The overarching goal of Dr. Tomko's research is to improve treatment outcomes for individuals with substance use disorders by understanding individual differences in substance use disorder presentation and identifying which treatments are optimal for a specific individual.